Skip to content
Life Sciences Series A Founded 2017

Spiderwort

Spiderwort is a developer of plant-based biomaterials for repair and regeneration of tissues. The company has developed an open-source platform that uses plant-derived cellulose to create scaffold architectures of organs. Products include CelluBridge, a proprietary plant-based biomaterial that promotes the repair and regeneration of the spinal cord, and CelluJuve, a plant-based dermal filler that can assist with…

📍 Ottawa, Canada · Regenerative Medicine,

Funding snapshot

Last roundSeries A
Amount$13M
Date12 July 2022
Total raised$16M
Team size18

About

Spiderwort is a developer of plant-based biomaterials for repair and regeneration of tissues. The company has developed an open-source platform that uses plant-derived cellulose to create scaffold architectures of organs. Products include CelluBridge, a proprietary plant-based biomaterial that promotes the repair and regeneration of the spinal cord, and CelluJuve, a plant-based dermal filler that can assist with injury recovery and cosmetic enhancement. Spiderwort leverages cellulose-based biomaterials to create biocompatible scaffolds that support tissue growth and healing, offering sustainable alternatives to synthetic and animal-derived biomaterials. Founded in 2017 and headquartered in Ottawa, Canada, Spiderwort has raised approximately 16.1 million at the Series A stage with investors including Horizons Ventures, K5 Global, Anges Quebec, BoxOne Ventures, Ontario Brain Institute, and Flucas Ventures.

Business model

Advanced Materials > Biomaterials > Bio Composites > Cellulose Fiber

Institutional investors

Horizons Ventures K5 Global Break Off Capital Angels Network Anges Quebec BoxOne Ventures Startup Garage Ontario Brain Institute Invest Ottawa Flucas Ventures Bayview Yards Andrew Waitman

Latest coverage

No articles yet.

Raising like Spiderwort?

Analyze your pitch deck before your next raise.

Analyze My Deck →